Application Of Suspension Array Technology In Individual Chemotherapy For Non-small Cell Lung Cancer

Background:Primary bronchial lung cancer, abbreviated as lung cancer, is a kind of malignant tumor deriving from bronchial mucous membrane or gland . It is one of the most common malignant tumour in the world. accounts for 16% of all malignant tumour, 28 percent of all cancer deaths. its morbidity has had the tendency to rise obviously in the past 50 years. In the past 10 years, the global incidence rate of lung cancer increases at the speed of 22% every year, there are 1.2 million new cases and 1.1 million deaths each year. In the worldwide, both men and women, lung cancer has become the leading cause of cancer deaths. The incidence rate of lung cancer in China takes the first place of malignant tumour in the city at present, occupies the 3rd place in the rural areas. Since 1996, lung cancer of our country had already occupied the first place in the cause of the cancer deaths. Non-small cell lung cancer is the main pathological types of lung cancer, accounting for 80 percent. lung cancer in early stage has no obvious or only mild symptoms.When the patients go to a doctor after having obviously clinical symptoms, they have mostly already belonged to the later period so that clinical treatment and the median survival period are unsatisfactory. At present, the clinical diagnosis of lung cancer rely mainly on imaging, Cytopathology and the organization,etc.However,these traditional methods lack sufficient sensitivity and specificity.70% of the NSCLC is already in advanced when found, which losesn the opportunity to surgery and multi-disciplinary complex treatment. chemotherapy as an important component of the comprehensive treatment, is the primary means of treatment. However, due to heterogeneity among individual presence, patients with the same pathological type and stage of NSCLC have great differences in sensitivity to the standard chemotherapy ,and more toxic side effects of chemtherapy for patients. But the effective rate of chemotherapy is only 20%—40%, the median survival is 8-10months, the 5-year survival rate is less than 15%.Along with deep scientific research and continual development of phar- macogenetics and pharmacogenomics,we can use the Individual chemotherapy plans for the patients."tailor"chemotherapy is that we can use the most powerful chemotherapy drugs by genetic characters in Patients. And improve clinical treatment effect and the median survival period.They that tumor location,the histological type,TNM stage,PS score and toxic side effects are useful for making chemotherapy plans for the patients,and the different expressions of the molecular markers that may be related to the efficacy of different chemotherapeutic agents and prognosis are more important in making chemotherapy plans.we have realized the different expression of ERCC1,RRM1,Beta-tubulin may be related to the efficacy of diferent chemotherapeutic agents and prognosis in NSCLC.So it is possible for predicting results of chemotherapeutic agents with those different markers.That ERCC1 is down-regulated can add chemotherapeutic Sensitivity to Platinum, On the other hand,it can leads to the resistance to Platinum. For patients of the different expression of RRM1,the minimal expression may be extremely effective. The effective rate of patients with of high expression Beta-tubulin were less than minimal expressions.Suspension array technology was product in 20 century 90 years by America Luminex conpany,it is combination of flow cytometry and chip technology. It is a new type of biochip with 100 different kinds of fluorescent beads as carriers of different probes and the reaction of biomolecules is finished in suspenseful liquid system. It is a flexible technical platform , which is used for protein analysis , nucleic acid analysis and so on. Compared with traditional biochip , the advantages of liquichip are accuracy , reliable and high reproducibility. The multiplexed bead-based immunoassay is a sensitive, reproducible and a high-throughput method. This method may further be developed for clinical application.Objective:To measure the levels of the expressions of the key gene in non-small cell lung cancer patients,which can predict the chemosensitivity by using suspension array technology.Material and Method:1.Patients choose 30 patients from 2009 October to 2010 March,the lung cancer patients who see the doctor in the Affiliated Tumor Hospital of Guangzhou medical college.2.Processing of sample Samples were fixed by 75% alcohol,Used suspension array Kit of Guang-zhou SUREXAM Biotechnology Co.Ltd to extract MRNA, incubation,use Luminex.3.The Suspension array technology examination Start Luminex instrument,put Sample in the reaction liquid on the tray,input Parameter settings and the ocation of the sample hole in orifice plate, reading data results in the Luminex instrument.Results:1. The expression of ERCC1mRNA:19 patients were minimal expression,10 patients were moderate expression, 1 patients was high expression.2. The expression of RRM1mRNA: 3 patients were minimal expression,14 patients were moderate expression, 13 patients was high expression.3. The expression of TUBB3mRNA: 13 patients were minimal expression, 10 patients were moderate expression, 7 patients was high expression.4. The expression of ERCC1mRNA and RRM1mRNA: 3 patients were all minimal expression, 8 patients were moderate and minimal expression, 6 patients was moderate expression.5. The expression of ERCC1mRNA and TUBB3mRNA: 9 patients were all minimal expression, 12 patients were moderate and minimal expression, 1 patients was moderate expression.Conclusions:The advantages of suspension array technology are easy operation , the high- throughput , the high-sensitivity , the high-accuracy , the high precision to detect the expression of ERCC1mRNA,RRM1mRNA and TUBB3mRNA in non-small cell lung cancer patients. Suspension array technology is a new type of biochip,it must have a good prospect of application and extension. we have realized the different expression of ERCC1,RRM1,Beta-tubulin may be related to the efficacy of diferent chemotherapeutic agents an d prognosis in NSCLC . So it is possible for predicting results of chemotherapeutic agents with those different markers.It can improve the effect of chemotherapy, and make truly individual therapy.